A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Safety and Tolerability of Oral PIPE-307 in Subjects with Relapsing-Remitting Multiple Sclerosis
Research Grant
Awarded By
Pipeline Therapeutics, Inc
Start Date
January 27, 2022
End Date
January 31, 2024
Awarded By
Pipeline Therapeutics, Inc
Start Date
January 27, 2022
End Date
January 31, 2024